UTHR
Neutral signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
United Therapeutics Corporation
- Nom
- United Therapeutics Corporation
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $25.1B
- Employés
- 1,400
- PDG
- Martine A. Rothblatt
- Site web
- https://www.unither.com
- Marché
- IKTINSMLQDATVTX
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 228 titres (~115 319,39 $ US)
- Insiders
- Mesa Nilda
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$8,611,820
Avg sell (VWAP, 90d window) $515.15 vs last close $592.84 (+15.1%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$8,562,234 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-14
- Liquidity
- Liquid $551,756,573/day · 20d vol
- Last synced
-
2026-10-27 04:43:11
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-15 | MAHON PAUL A | Sell · S · 10b5-1 | 719 | $546.56 | $392,977 | Form 4 |
| 2026-10-01 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 360 | $584.66 | $210,478 | Form 4 |
| 2026-10-01 | MAHON PAUL A | Sell · S · 10b5-1 | 160 | $573.15 | $91,704 | Form 4 |
| 2026-09-30 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 360 | $546.23 | $196,644 | Form 4 |
| 2026-09-29 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 200 | $486.77 | $97,354 | Form 4 |
| 2026-09-28 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 160 | $486.00 | $77,761 | Form 4 |
| 2026-09-25 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 632 | $478.95 | $302,698 | Form 4 |
| 2026-09-24 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 40 | $480.33 | $19,213 | Form 4 |
| 2026-09-23 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 240 | $500.05 | $120,012 | Form 4 |
| 2026-09-22 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 160 | $499.07 | $79,851 | Form 4 |
| 2026-09-21 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 843 | $496.62 | $418,654 | Form 4 |
| 2026-09-18 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 160 | $498.25 | $79,720 | Form 4 |
| 2026-09-17 | MAHON PAUL A | Sell · S · 10b5-1 | 320 | $501.58 | $160,506 | Form 4 |
| 2026-09-17 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 160 | $501.60 | $80,256 | Form 4 |
| 2026-09-16 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 120 | $505.20 | $60,624 | Form 4 |
| 2026-09-15 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 650 | $504.57 | $327,971 | Form 4 |
| 2026-09-14 | Mesa Nilda | Sell · S | 98 | $505.98 | $49,586 | Form 4 |
| 2026-09-14 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 440 | $506.48 | $222,851 | Form 4 |
| 2026-09-11 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 280 | $508.21 | $142,299 | Form 4 |
| 2026-09-10 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 280 | $508.80 | $142,465 | Form 4 |
| 2026-09-09 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 200 | $509.00 | $101,800 | Form 4 |
| 2026-09-08 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 418 | $504.15 | $210,733 | Form 4 |
| 2026-09-04 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 320 | $491.69 | $157,342 | Form 4 |
| 2026-09-03 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 42 | $491.25 | $20,632 | Form 4 |
| 2026-09-03 | MAHON PAUL A | Sell · S · 10b5-1 | 320 | $490.88 | $157,083 | Form 4 |
| 2026-09-02 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 160 | $510.05 | $81,608 | Form 4 |
| 2026-09-01 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 80 | $516.62 | $41,330 | Form 4 |
| 2026-08-31 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 40 | $514.96 | $20,598 | Form 4 |
| 2026-08-28 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 200 | $524.42 | $104,884 | Form 4 |
| 2026-08-27 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 120 | $531.12 | $63,734 | Form 4 |
| 2026-08-26 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 40 | $521.48 | $20,859 | Form 4 |
| 2026-08-25 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 80 | $520.50 | $41,640 | Form 4 |
| 2026-08-24 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 1,305 | $513.35 | $669,921 | Form 4 |
| 2026-08-21 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 200 | $527.71 | $105,542 | Form 4 |
| 2026-08-20 | MAHON PAUL A | Sell · S · 10b5-1 | 120 | $527.21 | $63,265 | Form 4 |
| 2026-08-20 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 193 | $526.97 | $101,705 | Form 4 |
| 2026-08-19 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 80 | $535.22 | $42,817 | Form 4 |
| 2026-08-18 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 441 | $518.65 | $228,724 | Form 4 |
| 2026-08-17 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 1,683 | $508.17 | $855,254 | Form 4 |
| 2026-08-14 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 321 | $500.93 | $160,797 | Form 4 |
| 2026-08-13 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 240 | $512.36 | $122,966 | Form 4 |
| 2026-08-12 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 41 | $520.96 | $21,359 | Form 4 |
| 2026-08-11 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 280 | $531.01 | $148,683 | Form 4 |
| 2026-08-10 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 214 | $538.86 | $115,317 | Form 4 |
| 2026-08-07 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 120 | $540.32 | $64,838 | Form 4 |
| 2026-08-06 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 420 | $532.39 | $223,605 | Form 4 |
| 2026-08-06 | MAHON PAUL A | Sell · S · 10b5-1 | 320 | $522.39 | $167,166 | Form 4 |
| 2026-08-05 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 160 | $524.59 | $83,934 | Form 4 |
| 2026-08-04 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 299 | $520.49 | $155,626 | Form 4 |
| 2026-08-03 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 320 | $518.61 | $165,956 | Form 4 |
| 2026-07-31 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 238 | $522.88 | $124,444 | Form 4 |
| 2026-07-30 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 40 | $528.96 | $21,158 | Form 4 |
| 2026-07-29 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 1,240 | $525.46 | $651,575 | Form 4 |
| 2026-07-28 | ROTHBLATT MARTINE A | Sell · S · 10b5-1 | 40 | $532.49 | $21,300 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-10-31 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-06-11 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2023-05-12 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-05-12 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2022-03-01 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2022-03-01 | Michael T. McCaul | Purchase | $1,001 - $15,000 |
| 2022-01-28 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2022-01-28 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2019-03-06 | Donna Shalala | Sale (Full) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
UTHR combines exceptional financial health (95 liquidity, ~42% net margin, near-zero net debt) with a meaningful catalyst stack: a $2B buyback authorization, FDA clearance for the SUMMIT trial in PH-COPD, and an…
The first sentence of the analysis written for UTHR on 2026-10-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Congress Supports a bullish reading. 2 purchase disclosures year to date
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Supports a bullish reading. Current ratio 6.60 · operating margin 48%
Suggested stop 514.88, nearest stored support minus 0.5 ATR(13.2% under the last close). Reward/risk to the next stored resistance is 0.01. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-22 United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company''s Board of Directors has authorized a new share repurchase program for up to $2 billion of the company''s common stock, available through October 21, 2027. “We have the balance sheet and free cash flow to fund our long-term ambitions and the confidence to act decisively when our own shares represent a compelling invest.
- 2026-10-21 United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a press release that will be issued on Wednesday, November 4, 2026, at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast on Wednesday, November 4, 2026, at 9:00 a.m. Eastern Time that will be accessible at https://ir.unither.com/events-and-presentations. A rebroadcast.
- 2026-10-20 United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. The company celebrated the openi.
- 2026-10-20 United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm''s stock in a transaction on Friday, October 16th. The shares were sold at an average price of $534.66, for a total value of $5,079,270.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company,
- 2026-10-19 United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company''s investigational new drug application to proceed with the SUMMIT clinical trial of treprostinil SMI in PH-COPD. The phase 2, 16-week, double blind SUMMIT study will evaluate the safety and tolerability of treprostinil SMI in approximately 40 patie.
- 2026-10-18 United Therapeutics (NASDAQ:UTHR) CEO Sells $5,129,905.00 in Stock United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company''s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $539.99, for a total transaction of $5,129,905.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company''s
- 2026-10-18 United Therapeutics (NASDAQ:UTHR) Stock: Insider Paul Mahon Sells 8,300 Shares United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the business''s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $544.30, for a total transaction of $4,517,690.00. Following the completion of the transaction, the executive vice president owned 45,172
- 2026-10-17 2,241 United Therapeutics Corporation $UTHR Shares Sold by First Citizens Bank & Trust Co. First Citizens Bank and Trust Co. trimmed its position in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 59.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,522 shares of the biotechnology company''s stock after selling
- 2026-10-14 LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
- 2026-10-14 Liquidia shares surge 25% as settlement ends United Therapeutics litigation Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes. The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia''s inhaled treprostinil treatment for pulmonary arterial hypertension, a condition involving high blood pressure in the lungs.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 87.9% | 89.2% | 88.9% | 92.4% | 92.7% | |
| Ebit Margin | 54.5% | 55.0% | 57.3% | 51.1% | 40.8% | |
| Ebitda Margin | 57.2% | 57.5% | 59.6% | 53.7% | 43.7% | |
| Operating Profit Margin | 47.7% | 47.9% | 50.9% | 50.6% | 33.0% | |
| Pretax Profit Margin | 53.9% | 53.5% | 54.7% | 49.1% | 35.2% | |
| Continuous Operations Profit Margin | 41.9% | 41.5% | 42.3% | 37.6% | 28.2% | |
| Net Profit Margin | 41.9% | 41.5% | 42.3% | 37.6% | 28.2% | |
| Bottom Line Profit Margin | 41.9% | 41.5% | 42.3% | 37.6% | 28.2% | |
| Current Ratio | 6.605 | 5.248 | 4.414 | 9.849 | 7.608 | |
| Quick Ratio | 6.278 | 5.035 | 4.275 | 9.552 | 7.301 | |
| Solvency Ratio | 1.812 | 1.378 | 0.878 | 0.624 | 0.434 | |
| Cash Ratio | 2.778 | 2.299 | 1.501 | 2.801 | 2.930 | |
| Price To Earnings Ratio | 16.172 | 13.345 | 10.451 | 17.402 | 20.385 | |
| Price To Earnings Growth Ratio | 1.159 | 0.520 | 0.330 | 0.343 | -2.262 | |
| Forward Price To Earnings Growth Ratio | 1.159 | 0.520 | 0.330 | 0.343 | -2.262 | |
| Price To Earnings Diluted Ratio | 17.489 | 14.320 | 11.100 | 18.539 | 21.479 | |
| Price To Earnings Diluted Growth Ratio | 1.338 | 0.587 | 0.346 | 0.378 | -1.675 | |
| Price To Book Ratio | 3.042 | 2.475 | 1.719 | 2.638 | 2.451 | |
| Price To Sales Ratio | 6.782 | 5.543 | 4.421 | 6.535 | 5.756 | |
| Price To Free Cash Flow Ratio | 20.741 | 14.759 | 13.765 | 19.064 | 20.323 | |
| Price To Operating Cash Flow Ratio | 13.826 | 12.017 | 10.522 | 15.767 | 16.219 | |
| Debt To Assets Ratio | 0.005 | 0.041 | 0.098 | 0.132 | 0.155 | |
| Debt To Equity Ratio | 0.005 | 0.047 | 0.117 | 0.167 | 0.202 | |
| Debt To Capital Ratio | 0.005 | 0.044 | 0.105 | 0.143 | 0.168 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.048 | 0.143 | 0.168 | |
| Financial Leverage Ratio | 1.110 | 1.143 | 1.198 | 1.260 | 1.306 | |
| Working Capital Turnover Ratio | 1.014 | 0.978 | 0.805 | 0.766 | 0.873 | |
| Operating Cash Flow Ratio | 2.785 | 1.798 | 1.216 | 2.338 | 1.959 | |
| Operating Cash Flow Sales Ratio | 0.491 | 0.461 | 0.420 | 0.414 | 0.355 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.667 | 0.814 | 0.764 | 0.827 | 0.798 | |
| Debt Service Coverage Ratio | 73.836 | 3.822 | 2.389 | 25.216 | 33.263 | |
| Interest Coverage Ratio | 77.805 | 32.098 | 19.981 | 30.238 | 29.887 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 4.424 | 2.445 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 41.521 | 4.424 | 1.397 | 1.003 | 0.748 | |
| Capital Expenditure Coverage Ratio | 2.999 | 5.384 | 4.245 | 5.782 | 4.952 | |
| Dividend Paid And Capex Coverage Ratio | 2.999 | 5.384 | 4.245 | 5.782 | 4.952 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 11.031 | 8.795 | 7.054 | 12.008 | 13.039 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 87.9% | ▼-1.3% | ▼-2.3% |
| Ebit Margin | 54.5% | ▼-0.5% | ▲2.8% |
| Ebitda Margin | 57.1% | ▼-0.3% | ▲2.8% |
| Operating Profit Margin | 47.7% | ▼-0.2% | ▲1.7% |
| Pretax Profit Margin | 53.8% | ▲0.4% | ▲4.6% |
| Continuous Operations Profit Margin | 41.9% | ▲0.4% | ▲3.6% |
| Net Profit Margin | 41.9% | ▲0.4% | ▲3.6% |
| Bottom Line Profit Margin | 41.9% | ▲0.4% | ▲3.6% |
| Current Ratio | 6.604 | ▲1.356 | ▼-0.141 |
| Quick Ratio | 6.278 | ▲1.243 | ▼-0.210 |
| Solvency Ratio | 1.812 | ▲0.434 | ▲0.787 |
| Cash Ratio | 2.778 | ▲0.478 | ▲0.316 |
| Price To Earnings Ratio | 16.172 | ▲2.827 | ▲0.621 |
| Price To Earnings Growth Ratio | 1.159 | ▲0.639 | ▲1.141 |
| Forward Price To Earnings Growth Ratio | 1.159 | ▲0.639 | ▲1.141 |
| Price To Earnings Diluted Ratio | 17.489 | ▲3.169 | ▲0.904 |
| Price To Earnings Diluted Growth Ratio | 1.338 | ▲0.751 | ▲1.143 |
| Price To Book Ratio | 3.042 | ▲0.567 | ▲0.577 |
| Price To Sales Ratio | 6.782 | ▲1.239 | ▲0.975 |
| Price To Free Cash Flow Ratio | 20.741 | ▲5.982 | ▲3.011 |
| Price To Operating Cash Flow Ratio | 13.826 | ▲1.809 | ▲0.156 |
| Debt To Assets Ratio | 0.005 | ▼-0.036 | ▼-0.081 |
| Debt To Equity Ratio | 0.005 | ▼-0.041 | ▼-0.102 |
| Debt To Capital Ratio | 0.005 | ▼-0.039 | ▼-0.088 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.072 |
| Financial Leverage Ratio | 1.111 | ▼-0.032 | ▼-0.093 |
| Working Capital Turnover Ratio | 1.014 | ▲0.036 | ▲0.127 |
| Operating Cash Flow Ratio | 2.785 | ▲0.987 | ▲0.766 |
| Operating Cash Flow Sales Ratio | 0.490 | ▲0.029 | ▲0.062 |
| Free Cash Flow Operating Cash Flow Ratio | 0.667 | ▼-0.148 | ▼-0.107 |
| Debt Service Coverage Ratio | 73.836 | ▲70.014 | ▲46.131 |
| Interest Coverage Ratio | 77.805 | ▲45.707 | ▲39.803 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▼-4.424 | ▼-1.374 |
| Operating Cash Flow Coverage Ratio | 41.521 | ▲37.098 | ▲31.703 |
| Capital Expenditure Coverage Ratio | 2.999 | ▼-2.384 | ▼-1.673 |
| Dividend Paid And Capex Coverage Ratio | 2.999 | ▼-2.384 | ▼-1.673 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 11.031 | ▲2.236 | ▲0.645 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $21.59B | $15.95B | $10.29B | $12.65B | $9.70B | |
| Enterprise value | $20.07B | $14.55B | $9.78B | $12.49B | $9.61B | |
| EV / Sales | 6.30x | 5.06x | 4.20x | 6.45x | 5.70x | |
| EV / Op. cash flow | 12.85x | 10.96x | 10.00x | 15.57x | 16.06x | |
| EV / Free cash flow | 19.28x | 13.47x | 13.09x | 18.82x | 20.12x | |
| EV / EBITDA | 11.03x | 8.79x | 7.05x | 12.01x | 13.04x | |
| Net debt / EBITDA | -0.83x | -0.84x | -0.37x | -0.15x | -0.13x | |
| Current ratio | 6.61x | 5.25x | 4.41x | 9.85x | 7.61x | |
| Income quality | 1.17x | 1.11x | 0.99x | 1.10x | 1.26x | |
| Graham number | $330 | $291 | $246 | $195 | $145 | |
| Graham net-net | $25 | $58 | $44 | $40 | $20 | |
| Tax burden | 77.9% | 77.7% | 77.3% | 76.5% | 80.1% | |
| Interest burden | 98.9% | 97.3% | 95.6% | 96.1% | 86.5% | |
| Working capital | $3.14B | $3.14B | $2.75B | $3.04B | $2.02B | |
| Invested capital | $4.99B | $4.47B | $3.91B | $3.94B | $2.84B | |
| Return on assets | 16.9% | 16.2% | 13.7% | 12.0% | 9.2% | |
| Operating ROA | 19.9% | 19.0% | 17.9% | 17.5% | 11.4% | |
| Return on tangible assets | 17.2% | 16.5% | 14.0% | 12.1% | 9.3% | |
| Return on equity | 18.8% | 18.5% | 16.5% | 15.2% | 12.0% | |
| Return on invested capital | 16.1% | 15.4% | 13.5% | 13.1% | 9.2% | |
| Return on capital employed | 20.7% | 20.8% | 18.6% | 17.2% | 11.4% | |
| Earnings yield | 6.2% | 7.5% | 9.6% | 5.7% | 4.9% | |
| Free cash flow yield | 4.8% | 6.8% | 7.3% | 5.2% | 4.9% | |
| Capex / Op. cash flow | 33.3% | 18.6% | 23.6% | 17.3% | 20.2% | |
| Capex / Depreciation | 608.1% | 340.0% | 433.1% | 270.6% | 242.1% | |
| Capex / Sales | 16.4% | 8.6% | 9.9% | 7.2% | 7.2% | |
| SG&A / Sales | 23.0% | 22.2% | 20.5% | 25.2% | 27.7% | |
| R&D / Sales | 17.3% | 16.7% | 17.5% | 16.7% | 32.0% | |
| Stock comp / Sales | 4.6% | 5.0% | 1.7% | 5.5% | 8.2% | |
| Intangibles / Total assets | 1.5% | 1.5% | 1.6% | 0.7% | 0.9% | |
| Days sales outstanding | 40d | 35d | 44d | 42d | 43d | |
| Days payables outstanding | 7d | 7d | 8d | 10d | 11d | |
| Operating cycle | 214d | 222d | 202d | 295d | 323d | |
| Cash conversion cycle | 207d | 214d | 194d | 285d | 311d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years